Applied Biosystems and Eppendorf Announce Licensing Agreement
News Nov 14, 2005
Under the agreement, Eppendorf will have the right to manufacture and sell real-time thermal cyclers in the research and applied fields.
"This agreement with Eppendorf further validates the significance of Applied Biosystems' real-time thermal cycler technology," said Paul D. Grossman, Ph.D., Esq., Vice President, Strategic Planning, Business Development and Intellectual Property for Applied Biosystems.
"We may consider entering into additional licenses with high quality vendors under the right terms."
"We are pleased to announce our agreement with Applied Biosystems," said Klaus Fink, CEO and President of Eppendorf AG.
"We are committed to providing our customers with access to technologies that are of greatest importance for the life sciences sector."
"Our new product generation of real-time cyclers ensures best practices in laboratories in terms of productivity, simplicity, and ease of use."
The license to Eppendorf is based on U.S. Patent No. 6,814,934 and foreign equivalents.
The U.S. Patent & Trademark Office (USPTO) granted Applera this fundamental patent pertaining to real-time PCR instrumentation in November 2004.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.